Spikevax has been authorised by the MHRA as 'safe and effective' for use in 12–17-year olds.
Further informationView COVID-19 vaccines
'It is for the Joint Committee on Vaccination and Immunisation (JCVI) to advise on whether this age group should be vaccinated with the COVID-19 vaccine made by Moderna as part of the deployment programme,' said MHRA chief executive Dr June Raine.
No new side-effects of the mRNA vaccine were identified in children 12–17 years and the safety data in this age group was comparable with that seen in young adults. As in young adults, the majority of adverse events were mild to moderate and relating to reactogenicity, such as a sore arm or tiredness.
Dr Raine said: 'We have in place a comprehensive safety surveillance strategy for monitoring the safety of all UK-approved COVID-19 vaccines and this surveillance will include the 12- to 17-year age group.'
The Pfizer/BioNTech COVID-19 mRNA vaccine Comirnaty is also approved for use from 12 years. Suitable age groups and other key characteristics of COVID-19 vaccines are summarised in the quick-reference MIMS comparison table.